TMDX
TransMedics Group, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
80.28
▼ 2.71 (3.27%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
82.99
Day high
84.05
Day low
80.13
Volume
570.75K
Market cap
$2.78B
P/E (TTM)
20.80
52W range
60.11 – 156.00
Trailing performance
Returnvs SPY
1W
-4.51%
-6.5%
1M
-10.78%
-11.9%
3M
+13.97%
+9.4%
6M
-25.20%
-43.4%
YTD
-34.01%
-48.3%
1Y
-30.61%
-47.0%
3Y
+46.63%
-35.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TMDX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+143.50K
Net buying
Buy transactions
14
153.13K shares
Sell transactions
1
9.62K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | WEILL DAVID Director |
BUY | 1.34K | $109.06K | Direct |
| Aug 17, 26 | TOBIN JAMES R Director |
STOCK | 18.00K | $0 | Indirect |
| Jul 10, 26 | HERNANDEZ GERARDO Chief Financial Officer |
STOCK | 17.25K | $0 | Direct |
| Jul 10, 26 | HASSANEIN WALEED H Chief Executive Officer |
STOCK | 49.67K | $0 | Direct |
| Jul 10, 26 | CORCORAN NICHOLAS Officer |
STOCK | 11.73K | $0 | Direct |
| Jun 15, 26 | GUNDERSON THOMAS JAMES Director |
SELL | 9.62K | $722.38K | Direct |
| Jun 15, 26 | GUNDERSON THOMAS JAMES Director |
CONVERSION | 19.29K | $42.62K | Direct |
| May 20, 26 | KANIA EDWIN M JR Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | TOBIN JAMES R Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | RAINES MERILEE Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | GUNDERSON THOMAS JAMES Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | LOVELL STEPHANIE Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | BASILE EDWARD M. Director |
STOCK | 2.92K | $0 | Direct |
| May 20, 26 | WEILL DAVID Director |
STOCK | 2.92K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CECERE GIOVANNI |
Officer | 19.06K | Stock Award(Grant) |
CORCORAN NICHOLAS |
Officer | 41.56K | Stock Award(Grant) |
FORSYTH MATTHEW S |
General Counsel | 15.41K | Stock Award(Grant) |
GUNDERSON THOMAS JAMES |
Director | 16.64K | Sale |
HASSANEIN WALEED H |
Chief Executive Officer | 666.10K | Stock Award(Grant) |
HERNANDEZ GERARDO |
Chief Financial Officer | 31.93K | Stock Award(Grant) |
KANIA EDWIN M JR |
Director | 309.87K | Stock Award(Grant) |
KHAYAL TAMER I. |
Officer | 36.04K | Sale |
TOBIN JAMES R |
Director | — | Stock Gift |
WEILL DAVID |
Director | 16.39K | Purchase |
Fundamentals
Market cap$2.78B
Enterprise value$3.18B
Revenue (TTM)$668.47M
Gross profit$392.35M
EBITDA$115.63M
Net income$151.70M
EPS (TTM)$3.86
Free cash flow$44.50M
Total cash$472.68M
Total debt$867.72M
Book value / share$14.96
Shares outstanding34.68M
Float33.56M
Short % of float35.82%
Dividend yield0.00%
Beta (5Y)1.93
Valuation & profitability ratios
Trailing P/E20.80
Forward P/E35.61
PEG ratio0.71
Price / sales—
Price / book5.37
EV / revenue4.76
EV / EBITDA27.49
Gross margin58.69%
Operating margin12.50%
Profit margin22.69%
Return on equity36.29%
Return on assets4.33%
Debt / equity167.50
Current ratio6.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $605.49M | $441.54M | $241.62M | $93.46M | +37.1% |
| Operating revenue | $605.49M | $441.35M | $241.60M | $92.08M | +37.2% |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | +35.2% |
| Gross profit | $362.81M | $262.08M | $154.09M | $65.27M | +38.4% |
| Research & development | $69.06M | $55.97M | $63.27M | $26.81M | +23.4% |
| Selling, general & admin | $185.17M | $168.62M | $119.55M | $69.90M | +9.8% |
| Total operating expense | $254.22M | $224.59M | $182.82M | $96.71M | +13.2% |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | +189.6% |
| Net interest income | -$13.78M | -$14.41M | -$10.79M | -$3.73M | +4.4% |
| Pre-tax income | $107.52M | $35.78M | -$26.67M | -$36.16M | +200.5% |
| Tax provision | -$82.77M | $316.00K | -$1.64M | $66.00K | -26,292.7% |
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Net income to common | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Basic EPS | 5.60 | 1.07 | -0.77 | -1.23 | +423.4% |
| Diluted EPS | 4.87 | 1.01 | -0.77 | -1.23 | +382.2% |
| EBIT | $121.30M | $50.19M | -$15.88M | -$32.44M | +141.7% |
| EBITDA | $148.49M | $69.95M | -$7.70M | -$28.96M | +112.3% |
| Basic shares | 33.99M | 33.23M | 32.52M | 29.56M | +2.3% |
| Diluted shares | 40.54M | 35.22M | 32.52M | 29.56M | +15.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $488.37M | $336.65M | $394.81M | $201.18M | +45.1% |
| Cash & short-term investments | $488.37M | $336.65M | $394.81M | $201.18M | +45.1% |
| Accounts receivable | $84.28M | $97.72M | $63.58M | $27.61M | -13.8% |
| Inventory | $48.88M | $46.55M | $44.23M | $20.61M | +5.0% |
| Total current assets | $637.78M | $497.22M | $510.65M | $252.29M | +28.3% |
| Property, plant & equipment | $332.81M | $292.45M | $180.49M | $24.35M | +13.8% |
| Goodwill & intangibles | $13.50M | $13.70M | $14.34M | $0 | -1.5% |
| Total assets | $1.07B | $804.08M | $706.05M | $277.15M | +32.9% |
| Total current liabilities | $89.31M | $59.91M | $54.93M | $23.66M | +49.1% |
| Current debt | $10.00M | — | — | — | — |
| Long-term debt | $502.39M | $509.31M | $506.20M | $58.70M | -1.4% |
| Total debt | $519.28M | $518.29M | $515.95M | $67.56M | +0.2% |
| Total liabilities | $595.27M | $575.47M | $568.85M | $89.77M | +3.4% |
| Retained earnings | -$277.95M | -$468.24M | -$503.70M | -$478.68M | +40.6% |
| Shareholder equity | $473.10M | $228.60M | $137.20M | $187.38M | +107.0% |
| Working capital | $548.48M | $437.30M | $455.72M | $228.63M | +25.4% |
| Net tangible assets | $459.60M | $214.90M | $122.86M | $187.38M | +113.9% |
| Shares issued | 34.27M | 33.62M | 32.67M | 32.14M | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Depreciation & amortisation | $27.18M | $19.76M | $8.18M | $3.48M | +37.6% |
| Stock-based compensation | $36.86M | $33.22M | $19.79M | $10.32M | +10.9% |
| Change in working capital | $18.38M | -$45.00M | -$44.35M | -$26.76M | +140.8% |
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | +295.1% |
| Capital expenditure | -$59.25M | -$129.74M | -$179.06M | -$11.91M | +54.3% |
| Investing cash flow | -$59.25M | -$129.30M | -$193.95M | $54.51M | +54.2% |
| Financing cash flow | $16.86M | $22.87M | $400.42M | $167.93M | -26.3% |
| Free cash flow | $133.59M | -$80.94M | -$192.09M | -$57.72M | +265.0% |
| End cash position | $488.87M | $337.15M | $395.31M | $201.68M | +45.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | +9.2% |
| Operating revenue | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | +9.2% |
| Cost of revenue | $76.75M | $72.77M | $67.35M | $59.25M | $60.78M | +5.5% |
| Gross profit | $113.20M | $101.16M | $93.41M | $84.58M | $96.59M | +11.9% |
| Research & development | $31.63M | $24.88M | $20.70M | $15.26M | $15.93M | +27.1% |
| Selling, general & admin | $53.54M | $56.92M | $51.44M | $46.02M | $42.44M | -5.9% |
| Total operating expense | $89.46M | $87.86M | $72.14M | $61.27M | $60.02M | +1.8% |
| Operating income | $23.74M | $13.30M | $21.27M | $23.30M | $36.57M | +78.5% |
| Net interest income | -$4.22M | -$7.17M | -$11.45M | -$191.00K | -$976.00K | +41.1% |
| Pre-tax income | $19.41M | $8.48M | $21.63M | $23.03M | $36.18M | +128.7% |
| Tax provision | $4.72M | $1.17M | -$83.75M | -$1.29M | $1.27M | +303.7% |
| Net income | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Net income to common | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Basic EPS | 0.42 | 0.21 | 3.08 | 0.71 | 1.03 | +100.0% |
| Diluted EPS | 0.41 | 0.20 | 2.62 | 0.66 | 0.92 | +105.0% |
| EBIT | $26.63M | $15.65M | $24.99M | $26.52M | $39.66M | +70.1% |
| EBITDA | $36.87M | $27.52M | $32.45M | $33.37M | $46.39M | +34.0% |
| Basic shares | 34.58M | 34.38M | 34.22M | 34.11M | 33.91M | +0.6% |
| Diluted shares | 40.71M | 36.19M | 40.93M | 40.75M | 40.56M | +12.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $472.68M | $461.74M | $488.37M | $466.17M | $400.57M | +2.4% |
| Cash & short-term investments | $472.68M | $461.74M | $488.37M | $466.17M | $400.57M | +2.4% |
| Accounts receivable | $104.14M | $90.73M | $84.28M | $80.70M | $104.85M | +14.8% |
| Inventory | $54.14M | $49.89M | $48.88M | $44.51M | $38.87M | +8.5% |
| Total current assets | $651.12M | $619.28M | $637.78M | $613.00M | $558.13M | +5.1% |
| Property, plant & equipment | $702.42M | $700.97M | $332.81M | $318.76M | $318.07M | +0.2% |
| Goodwill & intangibles | $11.55M | $11.55M | $13.50M | $13.55M | $13.60M | 0.0% |
| Total assets | $1.46B | $1.43B | $1.07B | $946.03M | $890.52M | +2.1% |
| Total current liabilities | $98.28M | $91.92M | $89.31M | $79.72M | $56.62M | +6.9% |
| Current debt | $20.00M | $15.00M | $10.00M | $5.00M | — | +33.3% |
| Long-term debt | $494.00M | $498.19M | $502.39M | $506.69M | $510.89M | -0.8% |
| Total debt | $867.72M | $863.41M | $519.28M | $519.35M | $518.82M | +0.5% |
| Total liabilities | $946.34M | $940.81M | $595.27M | $590.83M | $572.42M | +0.6% |
| Retained earnings | -$255.95M | -$270.63M | -$277.95M | -$383.33M | -$407.65M | +5.4% |
| Shareholder equity | $518.05M | $494.01M | $473.10M | $355.20M | $318.10M | +4.9% |
| Working capital | $552.84M | $527.36M | $548.48M | $533.27M | $501.51M | +4.8% |
| Net tangible assets | $506.50M | $482.46M | $459.60M | $341.65M | $304.50M | +5.0% |
| Shares issued | 34.63M | 34.55M | 34.27M | 34.14M | 34.04M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Depreciation & amortisation | $10.24M | $11.86M | $7.47M | $6.85M | $6.73M | -13.7% |
| Stock-based compensation | $8.61M | $9.95M | $9.39M | $9.14M | $9.37M | -13.5% |
| Change in working capital | -$25.44M | -$11.35M | -$5.34M | $27.93M | $40.19M | -124.1% |
| Operating cash flow | $17.31M | $24.53M | $34.51M | $69.57M | $91.61M | -29.4% |
| Capital expenditure | -$7.09M | -$36.66M | -$15.51M | -$7.62M | -$9.07M | +80.7% |
| Investing cash flow | -$7.09M | -$36.66M | -$15.51M | -$7.62M | -$9.07M | +80.7% |
| Financing cash flow | $970.00K | $3.76M | $3.10M | $3.64M | $7.09M | -74.2% |
| Free cash flow | $10.22M | -$12.12M | $19.00M | $61.95M | $82.53M | +184.3% |
| End cash position | $491.11M | $480.18M | $488.87M | $466.67M | $401.07M | +2.3% |
Options analytics
Put / call volume
12.74
Put-heavy session
Put / call open interest
0.74
Positioning, not flow
Max pain
76.00
-5.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
237
Contracts, this expiry
Put volume
3.02K
Contracts, this expiry
Heaviest call OI
95.00
46 contracts
Heaviest put OI
71.00
52 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.48 | 0.44 | -7.4% |
| Mar 2026 | 0.61 | 0.30 | -50.9% |
| Dec 2025 | 0.37 | 0.53 | +40.9% |
| Sep 2025 | 0.36 | 0.66 | +83.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.29 | 9 | $177.53M | +23.4% |
| Next quarter | 0.50 | 8 | $201.27M | +25.2% |
| Current year | 1.50 | 9 | $741.71M | +22.5% |
| Next year | 2.26 | 9 | $874.73M | +17.9% |
Analyst targets & ownership
Mean target$97.80
High target$125.00
Low target$65.00
Implied upside21.82%
Analyst count10
ConsensusBUY
Strong buy / Buy2 / 6
Hold4
Sell / Strong sell0 / 0
Held by insiders3.64%
Held by institutions103.01%
Institutions holding489
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
82.81
-3.06% from price
SMA 20
84.59
-5.09% from price
SMA 50
85.59
-6.20% from price
SMA 100
78.49
+2.28% from price
SMA 200
99.57
-19.37% from price
EMA 12
82.95
-3.22% from price
EMA 26
84.30
-4.77% from price
EMA 50
84.10
-4.54% from price
RSI (14)
42.4
Neutral
MACD (12,26,9)
-1.35
Hist -0.67
ATR (14)
3.94
4.91% of price
Realised vol 30D
41.8%
Annualised
Bollinger upper
90.07
20, 2σ
Bollinger lower
79.10
20, 2σ
50 / 200 cross
Death
85.59 vs 99.57
Trend bias
Below 200
-19.37%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.13
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
41.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.8%
Peak to trough
Max drawdown 5Y
-67.8%
Peak to trough
ATR 14
3.94
4.91% of price
Beta (reported)
1.93
5Y monthly, from filing
Short interest
Shares short
7.98M
Prior 7.91M
Change vs prior
+0.8%
Shorts adding
% of float
35.82%
Heavily shorted
% of shares out
23.01%
Against total outstanding
Days to cover
11.4
Crowded exit
Float
33.56M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 5, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Aug 5, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 3, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 28, 26 | UBS | INITIATED | — | Neutral |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 1, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jun 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 18, 26 | Stifel | MAINTAINED | Hold | Hold |
| May 26, 26 | Stifel | MAINTAINED | Hold | Hold |
| May 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 6, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-04
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-21
Proxy Statements
DEFA14A · 2026-05-07
Periodic Financial Reports
10-Q · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-10
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
Simply Wall St. · 5d ago
TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds
Simply Wall St. · 5d ago
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
Motley Fool · 8d ago
2 Stocks Down 28% and 34% to Buy and Hold
Motley Fool · 22d ago
TransMedics Names Fernando Araujo as CFO; Maintains 2026 Revenue Outlook
MT Newswires · 27d ago
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
PR Newswire · 27d ago
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Zacks · 34d ago
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
Zacks · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.